In this video, you will hear about how to prepare for a visit with your hematologist and how to advocate for your needs to get the best possible care.
In this video, you will hear about how to prepare for a visit to your HTC, or Hemophilia Treatment Clinic. You will also learn a bit about the different healthcare providers available to you at an HTC.
Individuals with severe von Willebrand disease (VWD), the most rare and severe form of the condition, can experience a wide range of bleeding symptoms ranging from relatively mild to serious. Gastrointestinal (GI) tract bleeding, which can be very…
In keeping with the spirit of National Family Caregivers Month, November HANDI Highlights is dedicated to resources that help support the caregiving community. This edition includes resources that speak to challenges universal to all…
The National Bleeding Disorders Foundation (NBDF) has awarded six exceptional researchers and healthcare professionals with prestigious fellowships to advance bleeding disorders research and care. These awards are part of NBDF's $22 million…
The World Federation of Hemophilia (WFH) is currently seeking feedback from users of the WFH Guidelines for the Management of Hemophilia. The survey includes nine questions focused primarily on users’ experience and preferences, with the goal of…
Federal2024 Election & What to Expect for the End of the YearBeginning in 2025 with the 119th Congress and the January 20th Presidential Inauguration, Republicans will take control of the White House and the two chambers of…
A new study published in the journal Blood Advances describes a new initiative focused on traditionally underserved and underdiagnosed subgroup within the bleeding disorders community – hemophilia carriers/females with hemophilia. The study…
Star Therapeutics, a clinical stage biotechnology company headquartered in San Francisco, CA, recently announced new interim clinical trial data for their investigational von Willebrand disease therapy VGA039. The data comes from VIVID 2, a phase 1…
Sanofi has announced positive results from their pivotal LUNA 3 study, a phase 3 clinical trial of rilzabrutinib, the company’s investigational oral therapy developed to treat persistent or chronic primary immune thrombocytopenia (ITP). Primary…